ISR has observed use of Preferred Provider agreements and the proportion of outsourcing allocated to Preferred Providers increase over the past three years. Is it because PPAs are the best model for outsourced manufacturing?
Today, the success of your programs has never been more contingent upon selecting and working effectively with your service partners. This is what our annual CMO Leadership Awards are all about.
Outsourced Pharma brought together a panel of experts at sponsor companies to discuss specifically how small biopharma can compete for attention at CDMOs.
A look at the benefits of using nanotechnology in drug development and the hurdles that must be overcome to entice a pharma company to offer nanotechnology alternatives to traditional therapy.
A summary of a survey designed to better understand the factors considered when establishing an analytical-testing strategy for clinical-material release.
Tim Scott, founder and CEO at both a CDMO and start-up biotech, maps out financial understanding for leaders of both approaches.
“Blockchain also can have a role in contract manufacturing, particularly in the technology transfer to a contract manufacturer in Phase 2 studies.”
Three cell and gene therapy sector SMEs representing industry and academia explain supply chain challenges and viable solutions.
How one biotech started with a list of 35 possible CDMOs and whittled that list down to two.
“FDA believes that quality agreements can be extremely valuable in delineating the activities of all parties involved in contract research and development arrangements.”